Consumer medicine information

Salofalk 1 g Suppository

Mesalazine

BRAND INFORMATION

Brand name

Salofalk Suppositories

Active ingredient

Mesalazine

Schedule

What is in this leaflet

This leaflet answers some common questions about SALOFALK. It does not contain all of the available information. Reading this leaflet does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the possible risks of using SALOFALK against the expected benefits.

Ask your doctor or pharmacist if you have any concerns about using SALOFALK.

Keep this leaflet with the medicine. You may want to read it again.

What SALOFALK is used for

SALOFALK suppositories contain the active ingredient, mesalazine (5-aminosalicylic acid) and are used to treat inflammatory bowel disease limited to the rectum.

Ask your doctor if you have any questions about why SALOFALK suppositories have been prescribed for you. Your doctor may have prescribed it for another reason.

SALOFALK is not addictive.

SALOFALK is not expected to affect your ability to drive a car or operate machinery.

SALOFALK is only available on a doctor’s prescription.

Before you use it

When you must not use it

Do not use SALOFALK if:

you are allergic to mesalazine or aspirin-like medicines, or any of the ingredients listed at the end of this leaflet.
Signs of allergic reactions may include itchy skin rash, shortness of breath and swelling of the face or tongue.
you suffer from a severe kidney or liver problem
the expiry date (EXP) printed on the pack has passed. If you use this medicine after the expiry date has passed, it may not work as well.
the package is torn or shows signs of tampering.

Do not give SALOFALK to a child below 12 years of age. The safety and effectiveness of SALOFALK in this group has not been established.

Before you start to use it

Tell your doctor if :

you have any allergies
you are pregnant or intend to become pregnant or are breastfeeding or wish to breastfeed.
Your doctor will discuss the risks and benefits of using SALOFALK if you are pregnant or breastfeeding.
you have or have had any medical conditions, especially lung or breathing problems such as asthma
you have kidney problems
Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine.
you have liver problems
You have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine.

If you have not told your doctor about any of the above, tell them before you start to use SALOFALK.

Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in Side effects section below.

Taking other medicines

Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

SALOFALK may interfere with the action of the following types of medicines:

anticoagulants, medicines used to stop blood clots, e.g. warfarin
glucocorticoids, medicines used to treat inflammation or swelling, e.g. prednisolone
sulphonylureas, medicines used to lower blood sugar
methotrexate, medicine used to treat some types of cancer and arthritis
probenecid/sulphinpyrazone, medicines used to treat gout
spironolactone/frusemide, medicines which lower blood pressure or increase volume of urine
rifampicin, medicine used to treat tuberculosis
azathioprine, medicine used to suppress the immune system
mercaptopurine or thioguanine, medicines used to treat leukaemia.

You may need to use different amounts of these medicines, or you may need to use different medicines when you are using SALOFALK. Your doctor or pharmacist will advise you.

How to use it

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

How much to use

Use one SALOFALK 1 g suppository once a day at bedtime.

How to use it

This medicine may only be administered into the back passage (rectum) therefore the suppository has to be inserted through the anus.

Do not swallow. It is not intended to be used by mouth.

Directions for use:

Empty your bowels if necessary and wash your hands.
Remove a suppository from the plastic strip.
Lie down on your left side with the left leg outstretched and the right leg bent.
Gently insert the suppository – pointed end first, into the rectum and then try to remain lying on your left side for one hour as this will aid the action of the suppositories.
Wash your hands again.

When to use it

SALOFALK 1 g suppositories should be administered preferably at bedtime.

Use SALOFALK the same time each day. This will help you remember when to use it.

How long to use it

SALOFALK helps control your condition but does not cure it. Therefore, you must continue to use SALOFALK for as long as your doctor tells you to.

If you forget to use it

If you forget to use a dose of SALOFALK, leave out that dose completely.

Administer your next dose at the normal time it is due.

Do not use a double dose to make up for the dose that you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you use to much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at the nearest hospital if you think that you or anyone else may have used too many SALOFALK suppositories.

Do this even if there are no signs of discomfort or poisoning.

While you are using it

Things you must do

Make sure that all doctors and pharmacists who are treating you know you are using SALOFALK. Remind them if any new medicines are about to be started.

If you are going to have surgery, tell the surgeon or anaesthetist that you are using this medicine. It may affect other medicines used during surgery.

Tell your doctor immediately if you become pregnant while using this medicine.

Things that you must not do

Do not use SALOFALK to treat any complaint other than that directed by your doctor. It may not be safe to use SALOFALK for another complaint.

Do not give your medicine to anyone else, even if they have the same condition as you. It may not be safe for another person to use SALOFALK.

Do not stop using your SALOFALK or change the dosage without checking with your doctor.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using SALOFALK. Like all medicines, SALOFALK may have some side effects. Most side effects are mild and may disappear without stopping this medicine. However, some may be serious and need medical attention.

Ask your doctor or pharmacist to answer any questions you may have.

Mild effects:

Tell your doctor or pharmacist if you notice any of the following that are troublesome or ongoing:

headache
mild stomach pains
excessive gas in the stomach or bowel
increased number of bowel motions
constipation
diarrhoea
nausea (feeling sick)
rash or itchy skin
dizziness
common cold.

More serious effects:

Tell your doctor immediately if you notice any of the following:

fever, muscle aches and pains, painful joints and chest pain (sometimes spreading to the neck and shoulders, and sometimes fever)
mild skin rash, itching or hives
numbness or weakness of the arms and legs
pain in the upper belly (may be due to inflammation of the pancreas)
worsening of ulcerative colitis.

Tell your doctor immediately or go to Accident and Emergency at your nearest hospital if any of the following happens:

allergic reaction including swelling of limbs, face, lips, mouth or throat which may cause difficulty in swallowing or breathing
marked worsening of general health, especially if accompanied by fever and/or sore throat or mouth. Very rarely this can be due to a low white blood cell count (agranulocytosis), which may increase the risk of developing a serious infection.
Reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms.

Other rare events, which have been reported with mesalazine, include:

changes in kidney function and inflammation of the kidney
changes in blood test results such as low white blood cell and/or platelet counts
changes in liver function tests
liver disease with nausea, vomiting, loss of appetite, feeling generally unwell, fever, itching, yellowing of the skin and eyes, and dark coloured urine
changes relating to your heart
allergic, inflammatory or other lung conditions
shortness of breath, difficulty breathing, cough, wheezing, chest pain that worsens when breathing
increased sensitivity of the skin to sun and ultraviolet light (photosensitivity)
reversible decrease in semen production (oligospermia)
hair loss and the development of baldness (alopecia)
severe diarrhoea and abdominal pain due to an allergic reaction to this medicine (pancolitis).

Other events with unknown frequency, include:

kidney stones and associated kidney pain

As a precaution, your doctor may have your blood, liver and kidney tested regularly during treatment with SALOFALK.

Tell your doctor or pharmacist if you notice anything else that is making you feel unwell. Other side effects not listed above may also occur in some patients.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After using it

Storage

Keep SALOFALK in the original package until it is time to use them. If you remove the suppositories out of their packaging, they may not keep as well.

Keep SALOFALK in a cool dry place where the temperature stays below 25°C, protected from light.

Do not store it or any other medicine in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep SALOFALK where children cannot reach them. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop using SALOFALK or the expiry date has passed, ask your pharmacist what to do with any suppositories that are left over.

Product description

What it looks like

SALOFALK 1 g are light beige coloured, torpedo-shaped suppositories in white plastic strip packs.

Available in packs of 30.

Ingredients

Each SALOFALK suppository contains 1 g of the active ingredient, mesalazine.

Each SALOFALK suppository also contains hard fat.

Sponsor

Dr Falk Pharma Australia Pty
Ltd, 815 Pacific Highway,
Chatswood, NSW 2067

Australian Registration Number: AUST R 162341

SALOFALK® is a registered trademark of Dr. Falk Pharma GmbH, Germany.

This leaflet was revised in November 2020.

Published by MIMS June 2025

BRAND INFORMATION

Brand name

Salofalk Suppositories

Active ingredient

Mesalazine

Schedule

1 Name of Medicine

Salofalk mesalazine 1 g suppository: mesalazine.

2 Qualitative and Quantitative Composition

Salofalk suppositories contain 1 g mesalazine as the active ingredient.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Salofalk suppositories are light beige coloured, torpedo-shaped suppositories.

4 Clinical Particulars

4.1 Therapeutic Indications

Salofalk suppositories are indicated in the treatment of ulcerative proctitis.

4.2 Dose and Method of Administration

One Salofalk 1 g suppository should be inserted into the rectum once daily at bedtime. The best results are achieved if the bowels are evacuated prior to insertion of the Salofalk suppository.

Use in children.

Salofalk suppositories should not be used in children 12 years old and under, as there is little experience with this age group.

4.3 Contraindications

Salofalk suppositories are contraindicated in patients with the following:
hypersensitivity to salicylic acid, salicylic acid derivatives, e.g. mesalazine/ 5-ASA;
hypersensitivity to any other ingredients in the Salofalk suppository;
severe impairment of hepatic and renal function.

4.4 Special Warnings and Precautions for Use

Salofalk should be given/ used under medical supervision.

Use in pulmonary function impairment.

Mesalazine should be used/given with caution in patients with pulmonary function impairment, particularly asthma and in patients with known hypersensitivity to sulfasalazine containing preparations. Treatment in the latter patients should be instituted with careful medical supervision. Treatment should be discontinued immediately if symptoms of acute intolerance, e.g. cramps, acute abdominal pain, fever, severe headache and skin rash, occur.

Use in hepatic impairment.

Caution is recommended in patients with impaired hepatic function. Salofalk suppositories are contraindicated in patients with severe hepatic impairment (see Section 4.3 Contraindications).
As mesalazine might cause hepatic impairment due to hypersensitivity reactions, blood parameters, like blood counts and liver function and cholestasis parameters (e.g. ALT, AST, alkaline phosphatase, γGT) may be monitored like the renal parameters.

Blood dyscrasia.

Serious blood dyscrasias have been reported very rarely with mesalazine. Haematological investigations should be performed if patients suffer from unexplained haemorrhages, bruises, purpura, anaemia, fever or pharyngolaryngeal pain.
Salofalk should be discontinued in case of suspected or confirmed blood dyscrasia.

Epigastric pain.

Epigastric pain, also commonly associated with inflammatory bowel disease and prednisone or sulfasalazine therapy, should be investigated in order to exclude conditions such as pericarditis, hepatitis and pancreatitis either as adverse drug reactions to mesalazine or secondary manifestations of inflammatory bowel disease. Cardiac hypersensitivity reactions (myocarditis, and pericarditis) induced by mesalazine have been rarely reported. Salofalk should then be discontinued immediately if any of these reactions occur.

Use in renal impairment.

Mesalazine is not recommended in patients with impaired renal function. The blood and renal status should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, checks are recommended 14 days after commencement of treatment, then a further 2 to 3 times at 4-weekly intervals. If the findings are normal, follow-up tests should be conducted every three months or immediately if additional signs of the disorder occur. To check renal function, it is recommended that levels of serum urea (BUN) and creatinine be determined as well as performing a urine sediment test. Mesalazine-induced renal toxicity should be considered if renal function deteriorates during treatment. If this is the case, Salofalk should be discontinued immediately.

Nephrolithiasis.

Cases of nephrolithiasis have been reported with the use of mesalazine, including stones with mesalazine content. Ensure adequate fluid intake during treatment.

Severe cutaneous adverse reactions.

Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment. Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reaction, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.

Idiopathic intracranial hypertension.

Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.

Urine discoloration.

Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g. in toilets cleaned with sodium hypochlorite contained in certain bleaches).

Use in the elderly.

Specific clinical data in only elderly patients for mesalazine are not available, but mesalazine has been used in patients up to 75 years of age in clinical trials.

Paediatric use.

Salofalk 1 g suppositories should not be used in children 12 years old and under, as there is little experience with this age group.

Effects on laboratory tests.

Not known to interfere with laboratory tests or physical diagnostic agents.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Studies to evaluate the potential interaction between Salofalk suppositories and other drugs have not been performed. In common with other salicylates, interactions may occur during concomitant administration of mesalazine and the following drugs:

Coumarin-type anticoagulants.

Possible potentiation of the anticoagulant effect action (increasing the risk of gastrointestinal haemorrhage).

Glucocorticoids.

Possible increase in undesirable gastric effects.

Sulphonylureas.

Possible increase in the blood glucose-lowering effects.

Methotrexate.

Possible increase in toxic potential of methotrexate.

Probenecid/ sulphinpyrazone.

Possible attenuation of the uricosuric effects.

Spironolactone/ frusemide.

Possible attenuation of the diuretic effects.

Rifampicin.

Possible attenuation of the tuberculostatic effects.
There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.
In patients who are concomitantly treated with azathioprine, 6-mercaptopurine, or thioguanine, possible enhanced myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine should be taken into account.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Fertility and reproductive performance were not impaired in rats treated orally with mesalazine prior to and during mating (both sexes) and throughout gestation and lactation (females) at doses up to 320 mg/kg/day. This dose is less than the maximal recommended clinical dose of Salofalk tablets, and about the same as the maximal recommended clinical dose of Salofalk granules, on a body surface area basis.
(Category C)
There was no evidence of embryotoxicity or teratogenicity in rats and rabbits treated orally with mesalazine during the period of organogenesis at respective doses of up to 320 and 495 mg/kg/day. On a body surface area basis, these doses are about 0.5-2.5 times the maximal recommended clinical dose of Salofalk tablets, and about 1.0-3.5 times the maximal recommended clinical dose of Salofalk granules. Oral mesalazine does not indicate direct or indirect harmful effects with respect to parturition or postnatal development in animals.
Human data on use during pregnancy are limited. No adverse effect of mesalazine on pregnancy or on the health of the foetus/ newborn child was shown. To date no other relevant epidemiologic data are available. In one single case after oral use of 2-4 g mesalazine per day during the 3^rd and 5^th months of pregnancy, renal failure in the neonate was reported. Salofalk suppositories should only be used during pregnancy if the potential benefit outweighs the possible risk.
In rats, there were no adverse effects on dams or offspring from oral administration of mesalazine during late gestation and throughout lactation at doses up to 320 mg/kg/day. This dose is less than the maximal recommended clinical dose of Salofalk tablets, and about the same as the maximal recommended clinical dose of Salofalk granules, on a body surface area basis.
There has been a report of a patient receiving mesalazine suppositories during the lactation period. Twelve hours after the initial dose, the infant developed watery diarrhoea that disappeared on discontinuation of the mesalazine therapy but reappeared on rechallenge. There have been reports of mesalazine and of its metabolite N-acetyl-5-ASA found in breast milk. But, there is no experience with Salofalk suppositories in lactating women. Salofalk suppositories should not be used during lactation unless the likely benefit of treatment outweighs the potential risk. If the infant develops diarrhoea, the treatment should be temporarily discontinued and further medical advice sought.

4.7 Effects on Ability to Drive and Use Machines

Mesalazine is generally not expected to affect the ability of patients to drive or operate machinery.

4.8 Adverse Effects (Undesirable Effects)

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.
In a multi-centre, randomised, investigator blinded study (SAS-6/UCA) involving 403 patients with active ulcerative proctitis, the rate of patients reporting at least 1 adverse event is 2.5% and 3.4% in the 1 g and 500 mg suppository groups respectively. The adverse events reported are shown in Table 1.

The following adverse events presented by body system have been reported in international post marketing surveillance of all Salofalk preparations, including Salofalk suppositories. In many cases, the relationship to Salofalk treatment has not been established.
The common (≥ 1% - < 10%) adverse events were as follows:

Body as a whole - general disorders.

Headache.

Gastrointestinal.

Abdominal pain, diarrhoea, nausea and vomiting, flatulence, constipation, exacerbation of ulcerative colitis.

Skin and appendages disorder.

Rash including pruritus, urticaria.
The following additional adverse reactions were classified as uncommon being reported in < 1% of patients.

Body as a whole - general disorders.

Fever, allergic reaction.

Central and peripheral nervous systems disorders.

Dizziness, paraesthesia, peripheral neuropathy.

Collagen disorders.

Lupus erythematosus syndrome (as observed for preparations with a similar chemical structure).

Gastrointestinal system disorders.

Acute pancreatitis, pancolitis, neonate diarrhoea.

Liver and biliary system disorders.

Hepatitis, increased liver enzyme values (transaminase activity), intrahepatic cholestasis, increased bilirubin, changes in pancreatic enzymes (lipase and amylase increased), eosinophil count increased.

Musculo-skeletal system disorders.

Arthralgia, myalgia, myositis.

Myo-, endo-, pericardial and valve disorders.

Pericarditis, myocarditis, pericardial effusion.

Platelet, bleeding and clotting disorders.

Thrombocytopenia.

Red blood cell disorders.

Aplastic anaemia, haemolytic anaemia.

Reproductive system disorders.

Oligospermia (reversible).

Respiratory, thoracic and mediastinal disorders.

Allergic and fibrotic lung reactions, dyspnoea, cough, bronchospasm, pleural effusion, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis (In isolated cases hypersensitivity reactions, principally in the form of respiratory problems, may be experienced by non-asthmatics due to the content of sodium metabisulfite in enemas).

Skin and appendages disorders.

Alopecia, allergic exanthema, increased sweating.

Urinary system disorders.

Acute or chronic interstitial nephritis, renal insufficiency, renal failure, nephrotoxicity.

White cell and RES disorders.

Agranulocytosis, leukopenia, neutropenia, pancytopenia.
The following additional adverse events were classified as rare being reported in < 0.1% of patients:

Skin and appendages disorders.

Photosensitivity (more severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema).
The following additional adverse events were classified as very rare being reported in < 0.01% of patients:

Liver and biliary system disorders.

Cholestatic hepatitis.
The frequency of the following adverse events is not known (i.e. cannot be estimated from available data):

Urinary system disorders.

Nephrolithiasis (see Section 4.4 Special Warnings and Precautions for Use for further information).

Skin and subcutaneous tissue disorders SOC.

Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see Section 4.4).

Nervous system disorders.

Idiopathic intracranial hypertension (see Section 4.4).

4.9 Overdose

There are limited data on overdosage (e.g. intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity.
Possible symptoms may include nausea, vomiting and diarrhoea, and symptoms similar to salicylate overdose.
There is no specific antidote. General supportive and symptomatic measures are recommended.
For information on the management of overdosage, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Mesalazine has been identified as the active component of sulfasalazine in inflammatory bowel disease and is thought to have a topical action. The mechanism of action by which mesalazine protects the mucosa in chronic inflammatory bowel disease is not yet fully known.
Mesalazine seems to act in multiple ways against several inflammatory mediators and principles. The results of in vitro investigations indicate that inhibition of lipoxygenase may play a role. Effects on prostaglandin concentrations in the intestinal mucosa have also been demonstrated, as has an influence on leukotriene production. Mesalazine may also function as a radical scavenger of reactive oxygen compounds.

Clinical trials.

The criteria used to evaluate the efficacy of the substance in the therapy of ulcerative colitis are frequency of bowel movements, rectal haemorrhage, abdominal pain, general well-being, temperature, extraintestinal manifestations, erythrocyte sedimentation rate (ESR), and haemoglobin. These criteria have been summarised in the clinical activity index (CAI) to evaluate the efficacy of treatment for ulcerative colitis.
In a multi-centre, randomised, investigator blinded study (SAS-6/UCA) involving 403 patients over 6 weeks, the efficacy and safety of Salofalk 1 g suppository administered once daily at bedtime in the therapy of acute ulcerative proctitis was demonstrated to be therapeutically equivalent to that of Salofalk 500 mg suppository administered three times daily.
The primary efficacy variable was clinical remission, defined as Disease Activity Index (DAI) < 4 at the final visit. DAI is defined as the sum of the scores of four parameters: weekly stool frequency, weekly rectal bleeding, mucosal appearance and physician's rating of disease activity. See Tables 2 and 3.

Results of the studies show that Salofalk suppositories are well tolerated in patients with ulcerative proctitis.

5.2 Pharmacokinetic Properties

General considerations.

The efficacy of mesalazine (5-ASA) appears to be determined not by the systemic but the local availability of the substance at the target site.
There is little pharmacokinetic data available for rectal administered mesalazine in children. There is no pharmacokinetic data in the elderly using Salofalk suppositories.

Absorption.

The systemic absorption of mesalazine decreases in the intestinal tract from proximal to distal segments. Because of low systemic absorption rates from oral delayed release preparations or rectal applications forms of mesalazine, the main elimination route is via faeces.

Salofalk suppositories.

The mean peak plasma concentrations of mesalazine after a single rectal dose of 1 g mesalazine (Salofalk 1 g suppository) was 192 ± 125 nanogram/mL (range 19 - 557 nanogram/mL), while for the main metabolite N-Acetyl-5-ASA it was 402 ± 211 nanogram/mL (range 57 - 1070 nanogram/mL). Time to reach the peak plasma concentration of mesalazine was 7.1 ± 4.9 hr (range 0.3 - 24 hr). The plasma levels following rectal administration are lower than those following oral administration.
Pharmacokinetic data are summarised in Table 4 for Salofalk 1 g suppositories administered once daily in 48 healthy subjects:

Distribution.

The plasma protein binding of mesalazine and acetylated mesalazine is 43% and 78%, respectively.

Salofalk suppositories.

Scintigraphic studies of technetium-labelled mesalazine 500 mg suppositories showed peak spread of the mesalazine after 2-3 hours following the melting of the suppository due to body temperature. The spread of the mesalazine was limited primarily to the rectum and rectosigmoid junction.

Metabolism.

Metabolism of mesalazine occurs mainly in the intestinal mucosa and, to a lesser extent, in the liver. The main metabolite is N-acetyl-5-aminosalicylic acid, which is similar to mesalazine is predominantly eliminated by the renal and faecal routes. It appears to have no therapeutic activity or specific toxic effects. The acetylation step appears irreversible. As metabolism occurs mainly in the intestinal mucosa, it has not been possible to differentiate between a rapid and slow acetylation form as in the case of sulfasalazine/sulfapyridine.

Excretion.

Systemically absorbed mesalazine and N-acetyl-5-ASA are eliminated mainly via kidneys. Biliary excretion is a minor route of elimination.
After a single rectal dose of Salofalk 1 g suppository approximately 14% (sum of mesalazine and its metabolite N-acetyl-5-ASA) of the administered mesalazine dose was recovered in the urine during 48 hours.

5.3 Preclinical Safety Data

Genotoxicity.

There was no evidence of genotoxic potential with mesalazine in bacterial gene mutation assays, of chromosomal damage in mouse haematopoietic cells following a single oral dose, or of increases in sister chromatid exchange frequencies in Chinese hamster bone marrow following a single intraperitoneal dose.

Carcinogenicity.

There was no evidence of carcinogenicity in rats treated with mesalazine in the diet for 127 weeks at doses up to 320 mg/kg/day, associated with plasma concentrations of mesalazine and N-acetyl-5-ASA of at least 15 fold the respective clinical plasma C_max concentrations associated with a 1 g dose of Salofalk suppository.

6 Pharmaceutical Particulars

6.1 List of Excipients

Salofalk 1 g suppositories contain the excipient hard fat.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from light.

6.5 Nature and Contents of Container

Salofalk 1 g moulded suppositories are available in white PVC/PE strip packs. Pack sizes of 5 and 30 suppositories.
Not all pack sizes are currently available in Australia.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Mesalazine is a white to greyish, voluminous powder, slightly pink in colour. It is practically insoluble in ethanol (90%), methanol (70%), water, ether, and chloroform, soluble in HCl (warmed 10% solution); soluble in NaOH (10% solution, with salt formation).
Proper name: 5-Aminosalicylic Acid, chemical name: 2-hydroxy-5-aminobenzoic acid, also referred to as 5-amino salicylic acid or 5-ASA. C₇H₇NO₃ = 153.1.

Service Unavailable

Consumer medicine information

Salofalk 1 g Suppository

Mesalazine

Keep track of your medicines

BRAND INFORMATION

Salofalk 1 g Suppositories